Overview

EBV CAR-T Cells for Nasopharyngeal Carcinoma

Status:
Not yet recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
The aim of this study is to investigate the safety and preliminary efficacy of EBV CAR-T cells in the treatment of relapsed/refractory NPC
Phase:
Early Phase 1
Details
Lead Sponsor:
The Affiliated Hospital of Xuzhou Medical University
Collaborator:
Guangzhou Bioresette Biomedical Technology Co., Ltd.
Treatments:
Cyclophosphamide
Fludarabine